VIRX News and Press, Viracta Therapeutics Inc. From 06/28/23

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the relapsed or refractory EBV + peripheral T-cell lymp...

2023-05-19 17:30:11 ET Gainers: WISeKey International Holding ( WKEY ) +6% . Viracta Therapeutics ( VIRX ) +5% . Fossil Group ( FOSL ) +5% . OmniAb ( OABI ) +5% . Lifecore Biomedical ( LFCR ) +4% . Losers: Jupiter Wellnes...

2023-05-18 10:04:28 ET Gainers: Enveric Biosciences ( ENVB ) +68% . Alimera Sciences ( ALIM ) +35% . Corvus Pharmaceuticals ( CRVS ) +12% . Viracta Therapeutics ( VIRX ) +11% . Bullfrog AI Holdings ( BFRG ) +8% . Losers: N...

2023-05-17 12:56:05 ET Gainers: Immutep Limited ( IMMP ) +114% . WeTrade Group ( WETG ) +56% . Smart for Life ( SMFL ) +56% . National Western Life Group ( NWLI ) +40% . Bausch Health Companies ( BHC ) +37% . SelectQuote ( ...

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and...

2023-05-08 17:13:41 ET Viracta Therapeutics press release ( NASDAQ: VIRX ): Q1 GAAP EPS of -$0.32. Cash, cash equivalents and investments of $80.3 million as of March 31, 2023 provides anticipated cash runway into late 2024 For further details see: Viracta Therap...

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023 Enrollment into fifth dose level in the dose escalation portion of the P...

2023-05-03 02:56:35 ET Viracta Therapeutics ( NASDAQ: VIRX ) said on Tuesday that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023. Donald Strickland, M.D., Viracta’s Vice President, Cl...

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving ...

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...